Angion is a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company’s lead product candidate, ANG-3777, is an hepatocyte growth factor (HGF) mimetic and is currently being evaluated in a Phase 3 registration trial to improve graft function and reduce the severity and long-term sequelae of transplant-associated acute kidney injury, also known as delayed graft function (DGF), in patients at risk for kidney dysfunction. The Company is also investigating ANG-3777 in a Phase 2 clinical trial for the treatment of cardiac surgery associated acute kidney injury (CSA-AKI).